antioxidant · for chronic inflammation
Resveratrol
Switches on your cells’ repair pathways and quietens inflammatory signalling.
Say that in clinical terms
Activates SIRT1 and AMPK pathways, suppresses NF-kB nuclear translocation, reduces pro-inflammatory cytokines IL-6 and CRP.
How strong is the research?
Solid evidence
Industry funded
2 papers read, 2 supporting.
Who was studied: People who already had an inflammatory condition such as metabolic syndrome or fatty liver.
How much to take
daily
150–500 mg
Trans-resveratrol preferred. Take with fat for absorption.
Before you take it
- No NIH/IOM Tolerable Upper Intake Level (UL) established for resveratrol; gastrointestinal side effects (nausea, diarrhea, abdominal discomfort) have been reported at doses above 1000 mg/day in some trials; doses at and above 500 mg/day should be monitored.
- CYP2C9 and CYP3A4 inhibition demonstrated in vitro; clinical significance at standard supplement doses is uncertain, but potential exists to increase plasma concentrations of warfarin (bleeding risk), statins (myopathy risk), cyclosporine, and other CYP-metabolized drugs.
- Phytoestrogenic (estrogen receptor agonist) activity: use caution or avoid in individuals with hormone-sensitive cancers (breast, ovarian, uterine) or those on concurrent hormone replacement therapy or SERM treatment.
- Platelet aggregation inhibition: additive bleeding risk when combined with anticoagulants (warfarin, heparin), antiplatelet agents (aspirin, clopidogrel), or NSAIDs.
- Oral bioavailability is below 1% due to rapid first-pass sulfation and glucuronidation; achievable plasma and tissue concentrations from standard supplement doses are uncertain, and effects observed in vitro or at high parenteral doses may not translate to oral supplementation at typical label doses.
- Insufficient safety data in pregnancy and lactation; animal studies show phytoestrogenic and potential developmental effects; avoid during pregnancy and breastfeeding.
What we make of it
Our mechanism was wrong — pooled analyses find it does not lower the marker we named.
The detail
This contained a factual error. Several independent 2018 pooled analyses found resveratrol does not significantly reduce IL-6, which is the inflammation marker our mechanism claimed it acted on.